Vertex Pharmaceuticals reported that its cystic fibrosis (CF) franchise delivered over $100 million in 2025 revenue for CASGEVY, with more than 60 patient infusions recorded last year. The company raised its estimate of people living with CF in target markets to approximately 112,000 globally, including roughly 97,000 in core markets such as the United States, Europe and Canada. This expansion reflects increased diagnostic uptake, broader genetic testing and improved access programs in emerging regions, positioning Vertex as the leading commercial provider of CF modulators worldwide.

Vertex plans to complete its rolling BLA filing for U.S. accelerated approval of povetacicept in immunoglobulin A nephropathy (IgAN) in the first half of 2026. The submission will leverage a priority review voucher to reduce FDA review time from ten to six months. Povetacicept, a novel dual-target B-cell–activating factor inhibitor, has shown in Phase 2 studies a mean reduction in proteinuria of 45% at Week 24, with stable estimated glomerular filtration rate (eGFR), supporting its potential to address an $8 billion global kidney disease market.

Vertex is on track to complete enrollment in two Phase 3 studies of suzetrigine for diabetic peripheral neuropathy by the end of 2026, following positive Phase 2 outcomes that demonstrated a 30% improvement in pain scores versus placebo at 12 weeks. Additionally, the company plans to advance its emerging renal franchise beyond IgAN, including preclinical programs in polycystic kidney disease and focal segmental glomerulosclerosis. In parallel, over 500,000 prescriptions of JOURNAVX for transthyretin amyloidosis cardiomyopathy were written and filled in 2025, underscoring Vertex’s growing presence in rare genetic disorders.

Building on a year of robust revenue growth and rapid R&D progress, Vertex management highlighted several catalysts for 2026: BLA decisions for povetacicept, topline data from the suzetrigine Phase 3 trials, and potential regulatory filings for next-generation CF modulators. The company’s cash runway, supported by strong operating cash flow and an unutilized $2.5 billion credit facility, is expected to fund pivotal studies and commercial launches through 2028. Investor focus will center on data readouts and FDA decisions that could unlock an estimated $15 billion in incremental peak sales across kidney and neuropathy indications.